151 related articles for article (PubMed ID: 28245763)
1. Recent Advances of Hepsin-Targeted Inhibitors.
Kwon H; Han J; Lee KY; Son SH; Byun Y
Curr Med Chem; 2017; 24(21):2294-2311. PubMed ID: 28245763
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship studies of dipeptide-based hepsin inhibitors with Arg bioisosteres.
Kwon H; Ha H; Jeon H; Jang J; Son SH; Lee K; Park SK; Byun Y
Bioorg Chem; 2021 Feb; 107():104521. PubMed ID: 33334587
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design, synthesis, and biological evaluation of Leu-Arg dipeptide analogs as novel hepsin inhibitors.
Kwon H; Kim Y; Park K; Choi SA; Son SH; Byun Y
Bioorg Med Chem Lett; 2016 Jan; 26(2):310-314. PubMed ID: 26711145
[TBL] [Abstract][Full Text] [Related]
4. Recent progress on inhibitors of the type II transmembrane serine proteases, hepsin, matriptase and matriptase-2.
Damalanka VC; Janetka JW
Future Med Chem; 2019 Apr; 11(7):743-769. PubMed ID: 30945556
[TBL] [Abstract][Full Text] [Related]
5. Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.
Goswami R; Wohlfahrt G; Törmäkangas O; Moilanen A; Lakshminarasimhan A; Nagaraj J; Arumugam KN; Mukherjee S; Chacko AR; Krishnamurthy NR; Jaleel M; Palakurthy RK; Samiulla DS; Ramachandra M
Bioorg Med Chem Lett; 2015 Nov; 25(22):5309-14. PubMed ID: 26421993
[TBL] [Abstract][Full Text] [Related]
6. Allosteric antibody inhibition of human hepsin protease.
Koschubs T; Dengl S; Dürr H; Kaluza K; Georges G; Hartl C; Jennewein S; Lanzendörfer M; Auer J; Stern A; Huang KS; Packman K; Gubler U; Kostrewa D; Ries S; Hansen S; Kohnert U; Cramer P; Mundigl O
Biochem J; 2012 Mar; 442(3):483-94. PubMed ID: 22132769
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of dye-conjugated hepsin inhibitors.
Kim K; Kwon H; Choi D; Lim T; Minn I; Son SH; Byun Y
Bioorg Chem; 2019 Aug; 89():102990. PubMed ID: 31136899
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology.
Damalanka VC; Han Z; Karmakar P; O'Donoghue AJ; La Greca F; Kim T; Pant SM; Helander J; Klefström J; Craik CS; Janetka JW
J Med Chem; 2019 Jan; 62(2):480-490. PubMed ID: 30571119
[TBL] [Abstract][Full Text] [Related]
9. Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
Xuan JA; Schneider D; Toy P; Lin R; Newton A; Zhu Y; Finster S; Vogel D; Mintzer B; Dinter H; Light D; Parry R; Polokoff M; Whitlow M; Wu Q; Parry G
Cancer Res; 2006 Apr; 66(7):3611-9. PubMed ID: 16585186
[TBL] [Abstract][Full Text] [Related]
10. Structure-Based Design of High-Affinity and Selective Peptidomimetic Hepsin Inhibitors.
Knaff PM; Müller P; Kersten C; Wettstein L; Münch J; Landfester K; Mailänder V
Biomacromolecules; 2022 Jun; 23(6):2236-2242. PubMed ID: 35593713
[TBL] [Abstract][Full Text] [Related]
11. Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.
Franco FM; Jones DE; Harris PK; Han Z; Wildman SA; Jarvis CM; Janetka JW
Bioorg Med Chem; 2015 May; 23(10):2328-43. PubMed ID: 25882520
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.
Subedi M; Minn I; Chen J; Kim Y; Ok K; Jung YW; Pomper MG; Byun Y
Eur J Med Chem; 2016 Aug; 118():208-218. PubMed ID: 27128184
[TBL] [Abstract][Full Text] [Related]
13. α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer.
Han Z; Harris PK; Karmakar P; Kim T; Owusu BY; Wildman SA; Klampfer L; Janetka JW
ChemMedChem; 2016 Mar; 11(6):585-99. PubMed ID: 26889658
[TBL] [Abstract][Full Text] [Related]
14. Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis.
Tang X; Mahajan SS; Nguyen LT; Béliveau F; Leduc R; Simon JA; Vasioukhin V
Oncotarget; 2014 Mar; 5(5):1352-62. PubMed ID: 24657880
[TBL] [Abstract][Full Text] [Related]
15. Metal mediated protease inhibition: design and synthesis of inhibitors of the human cytomegalovirus (hCMV) protease.
Dhanak D; Burton G; Christmann LT; Darcy MG; Elrod KC; Kaura A; Keenan RM; Link JO; Peishoff CE; Shah DH
Bioorg Med Chem Lett; 2000 Oct; 10(20):2279-82. PubMed ID: 11055338
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of small-molecule inhibitors of hepsin.
Chevillet JR; Park GJ; Bedalov A; Simon JA; Vasioukhin VI
Mol Cancer Ther; 2008 Oct; 7(10):3343-51. PubMed ID: 18852137
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationships of a new class of 1-oxacephem-based human chymase inhibitors.
Aoyama Y; Uenaka M; Konoike T; Iso Y; Nishitani Y; Kanda A; Naya N; Nakajima M
Bioorg Med Chem Lett; 2000 Nov; 10(21):2397-401. PubMed ID: 11078187
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of redox stable analogues of sunflower trypsin inhibitors (SFTI-1) on solid support, potent inhibitors of matriptase.
Jiang S; Li P; Lee SL; Lin CY; Long YQ; Johnson MD; Dickson RB; Roller PP
Org Lett; 2007 Jan; 9(1):9-12. PubMed ID: 17192072
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of bisbenzamidines as inhibitors for matriptase-2.
Beckmann AM; Gilberg E; Gattner S; Huang TL; Vanden Eynde JJ; Mayence A; Bajorath J; Stirnberg M; Gütschow M
Bioorg Med Chem Lett; 2016 Aug; 26(15):3741-5. PubMed ID: 27287367
[TBL] [Abstract][Full Text] [Related]
20. Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis.
Li W; Wang BE; Moran P; Lipari T; Ganesan R; Corpuz R; Ludlam MJ; Gogineni A; Koeppen H; Bunting S; Gao WQ; Kirchhofer D
Cancer Res; 2009 Nov; 69(21):8395-402. PubMed ID: 19843851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
